Merck (MRK) Asset Utilization Ratio (2009 - 2026)
Merck (MRK) posted quarterly Asset Utilization Ratio of 0.5 for Q1 2026, down 10.02% YoY from 0.55 in Q1 2025, and up 1.49% sequentially from 0.49 in Q4 2025.
Merck (MRK) Asset Utilization Ratio (2009 - 2026) Analysis & Trends
Merck has disclosed Asset Utilization Ratio across 18 years of filings, most recently posting 0.5 for Q1 2026.
- In Q1 2026, Asset Utilization Ratio fell 10.02% year-over-year to 0.5; the TTM figure through Mar 2026 stood at 0.5 (down 10.02% YoY), while the FY2025 annual figure was 0.51, down 10.73% from the prior year.
- Asset Utilization Ratio rose to 0.5 in Q1 2026, from 0.49 in the prior quarter.
- Over the last five years, Asset Utilization Ratio for MRK reached as high as 0.58 in Q1 2024 and fell as low as 0.49 in Q4 2025.
- The 5-year median for Asset Utilization Ratio is 0.55 (2022), against an average of 0.54.
- Annual changes were most pronounced in 2022 — Asset Utilization Ratio gained 12.12% — and 2025, when it declined 10.77%.
- A 5-year view of Asset Utilization Ratio shows it stood at 0.55 in 2022, then increased by 2.75% to 0.56 in 2023, then fell by 2.92% to 0.55 in 2024, then decreased by 10.77% to 0.49 in 2025, then increased by 1.49% to 0.5 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.5, 0.49, and 0.52 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 0.63 |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 0.48 |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 0.46 |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 0.50 |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 0.50 |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 0.41 |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 0.52 |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 0.12 |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 0.34 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.50 |
| Dec 31, 2025 | 0.49 |
| Sep 30, 2025 | 0.52 |
| Jun 30, 2025 | 0.55 |
| Mar 31, 2025 | 0.55 |
| Dec 31, 2024 | 0.55 |
| Sep 30, 2024 | 0.55 |
| Jun 30, 2024 | 0.57 |
| Mar 31, 2024 | 0.58 |
| Dec 31, 2023 | 0.56 |
| Sep 30, 2023 | 0.56 |
| Jun 30, 2023 | 0.55 |
| Mar 31, 2023 | 0.53 |
| Dec 31, 2022 | 0.55 |
| Sep 30, 2022 | 0.55 |
| Jun 30, 2022 | 0.53 |
| Mar 31, 2022 | 0.51 |
| Dec 31, 2021 | 0.49 |
| Sep 30, 2021 | 0.50 |
| Jun 30, 2021 | 0.48 |